Table 2. Stratified7+cyclin D1 expression and overall survival of HCC patients.

Variable	Total number	MCM7highor cyclin D1high		MCM7low and cyclin D1low		HR (95% CI)a	P-valuea
		Case number	MST (month)	Case number	MST (month)
Overall	153	87	25.0	66	>63.0	2.57 (1.61–4.10)	<0.001
Age
⩽55 years	93	51	25.0	42	48.0	2.43 (1.36–4.33)	0.003
> 55 years	60	36	24.0	24	>63.0	2.72 (1.22–6.06)	0.015
Gender
Male	101	57	20.0	44	>63.0	2.70 (1.46–5.01)	0.002
Female	52	30	26.0	22	46.0	2.61 (1.26–5.39)	0.01
Hepatitis virus infection
Negative	43	23	31.0	20	>63.0	3.73 (1.23–11.36)	0.02
Positive	110	64	17.0	46	46.0	2.37 (1.41–3.99)	0.001
Cirrhosis
Absent	55	28	42.0	27	>62.0	2.45 (1.00–6.01)	0.051
Present	98	59	15.0	39	48.0	2.54 (1.46–4.40)	0.001
Child–Pugh score
A+B	142	80	26.0	62	>63.0	2.53 (1.55–4.12)	<0.001
C	11	7	18.0	4	46.0	4.84 (0.57–40.86)	0.147
Serum AFP level
<200 ng/ml	76	37	31.0	39	>63.0	3.02 (1.47–6.23)	0.003
⩾200 ng/ml	77	50	13.0	27	37.0	1.95 (1.05–3.60)	0.034
Tumor size
⩽5 cm	99	50	28.0	49	>63.0	2.74 (1.49–5.05)	0.001
>5 cm	54	37	17.0	17	30.0	1.86 (0.88–3.94)	0.105
Tumor number
Single	103	56	24.0	47	>63.0	3.21 (1.77–5.83)	<0.001
Multiple (⩾2)	50	31	28.0	19	46.0	1.58 (0.74–3.38)	0.235
Capsule integrity
Yes	70	40	24.0	30	>63.0	2.60 (1.33–5.11)	0.005
No	83	47	25.0	36	48.0	2.47 (1.29–4.74)	0.006
Venous invasion
Negative	111	53	28.0	58	>63.0	2.53 (1.47–4.36)	0.001
Positive	42	34	13.0	8	16.0	1.61 (0.56–4.62)	0.375
Differentiation
Edmonson I–II	82	34	32.0	48	>63.0	2.25 (1.13–4.48)	0.021
Edmonson III–IV	71	53	22.0	18	37.0	1.82 (0.92–3.64)	0.088
TNM stage
I+II	112	55	28.0	57	>63.0	2.53 (1.45–4.40)	0.001
III	41	32	13.0	9	26.0	1.60 (0.61–4.19)	0.337
BCLC stage
A–B	106	52	28.0	54	>63.0	2.71 (1.55–4.75)	0.001
C	47	35	17.0	12	46.0	1.67 (0.69–4.06)	0.259

Abbreviations: CI, confidence interval; HR, hazard ratio; MST, median survival time

^aHR and P-value were derived from univariate analysis. The significant P-values (<0.05) are in bold